@article{3031869,
    title = "Colchicine Improves Clinical Outcomes and Quality of Life in
Hidradenitis Suppurativa Patients: A Retrospective Study",
    author = "Liakou, Aikaterini I. and Kontochristopoulos, Georgios and Agiasofitou, and Efthymia and Tsantes, Andreas G. and Papadakis, Marios and Marnelakis, and Ioannis and Tsante, Konstantina A. and Kapsiocha, Anastasia and and Katoulis, Alexandros and Gregoriou, Stamatios and Rigopoulos, Dimitris",
    journal = "Journal of Clinical Medicine Research",
    year = "2021",
    volume = "10",
    number = "20",
    publisher = "MDPI",
    issn = "1918-3003, 1918-3011",
    doi = "10.3390/jcm10204742",
    keywords = "colchicine; hidradenitis suppurativa; treatment; quality of life",
    abstract = "Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory
skin disorder of the follicular epithelium. The aim of the study was to
investigate the effectiveness of colchicine on the clinical outcomes of
HS patients, and to evaluate wither colchicine as monotherapy or in
combination with doxycycline would provide better outcomes. Methods: A
retrospective study was conducted including 44 patients with established
HS, divided into three groups. The first group (n = 15 patients)
received colchicine as monotherapy, the second group (n = 14 patients)
received colchicine and doxycycline 100 mg/d, while the third group (n =
15 patients) received colchicine and doxycycline 40 mg/d. Disease
severity during treatment was assessed at baseline and follow-up, using
the Hurley Scoring System and the International Hidradenitis Suppurativa
Severity Score System (IHS4). All patients were also asked to complete a
Dermatology Life Quality Index (DLQI) questionnaire. These scores were
compared among the study groups. Results: The DLQI and IHS4 scores
significantly improved after treatment with colchicine (p < 0.001) in
all groups. All colchicine regimes, including the single colchicine
regime, colchicine plus doxycycline 100 mg regime, and colchicine plus
doxycycline 40 mg regime, resulted in significant improvements in the
DLQI and IHS4 scores (p < 0.001). Clinical improvement based on DLQI and
IHS4 scores was similar in all groups. None of the patients had to
discontinue the treatment due to adverse events. Discussion: In
conclusion, our findings suggest that colchicine may improve clinical
severity and quality of life in HS patients, either as monotherapy or in
combination with doxycycline, both at antimicrobial (100 mg) and
sub-antimicrobial (40 mg) doses.</p>"
}